High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma

D Baiz; C Negroni; S Ferluga; E Ercolano; C Adams; CO Hanemann

High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma

D Baiz, C Negroni, S Ferluga, E Ercolano, C Adams, CO Hanemann

Peninsula Medical School

Research output: Contribution to conference › Abstract › peer-review

11 Downloads (Pure)

Abstract

Meningioma is the most common primary tumour affecting the central nervous system; it is classified as benign (WHO I, ~80%), atypical (WHO II, ~15-20%) and anaplastic/malignant (WHO III, ~1-3%). The 3-year recurrence rate in WHO I meningioma is estimated in about 50% and it is much greater in WHO II and III tumours. MicroRNAs (miRNAs) represent a large class of small RNAs driving regulation of gene expression at post-transcriptional level and playing a role in cell proliferation, differentiation, apoptosis and carcinogenesis. Several studies showed that miRNAs are involved in tumour progression and therefore proposed as diagnostic tools. Here, we evaluated miRNAs signature in meningioma to identify novel biomarkers of tumour progression.

Original language	English
Publication status	Published - 2018
Event	25th Biennial Congress of the European Association for Cancer Research (EACR25) - Amsterdam Duration: 30 Jun 2018 → 3 Jul 2018

Conference

Conference	25th Biennial Congress of the European Association for Cancer Research (EACR25)
Period	30/06/18 → 3/07/18

Access to Document

Abstract EACR 2018 DB miRNA finalFinal published version, 22.7 KBLicence: CC BY-NC-ND

Cite this

@conference{43c31d5948924fc0a9dfcb91b85eb2cd,

title = "High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma",

abstract = "Meningioma is the most common primary tumour affecting the central nervous system; it is classified as benign (WHO I, \textasciitilde{}80\%), atypical (WHO II, \textasciitilde{}15-20\%) and anaplastic/malignant (WHO III, \textasciitilde{}1-3\%). The 3-year recurrence rate in WHO I meningioma is estimated in about 50\% and it is much greater in WHO II and III tumours. MicroRNAs (miRNAs) represent a large class of small RNAs driving regulation of gene expression at post-transcriptional level and playing a role in cell proliferation, differentiation, apoptosis and carcinogenesis. Several studies showed that miRNAs are involved in tumour progression and therefore proposed as diagnostic tools. Here, we evaluated miRNAs signature in meningioma to identify novel biomarkers of tumour progression.",

author = "D Baiz and C Negroni and S Ferluga and E Ercolano and C Adams and CO Hanemann",

year = "2018",

language = "English",

note = "25th Biennial Congress of the European Association for Cancer Research (EACR25) ; Conference date: 30-06-2018 Through 03-07-2018",

}

TY - CONF

T1 - High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma

AU - Baiz, D

AU - Negroni, C

AU - Ferluga, S

AU - Ercolano, E

AU - Adams, C

AU - Hanemann, CO

PY - 2018

Y1 - 2018

N2 - Meningioma is the most common primary tumour affecting the central nervous system; it is classified as benign (WHO I, ~80%), atypical (WHO II, ~15-20%) and anaplastic/malignant (WHO III, ~1-3%). The 3-year recurrence rate in WHO I meningioma is estimated in about 50% and it is much greater in WHO II and III tumours. MicroRNAs (miRNAs) represent a large class of small RNAs driving regulation of gene expression at post-transcriptional level and playing a role in cell proliferation, differentiation, apoptosis and carcinogenesis. Several studies showed that miRNAs are involved in tumour progression and therefore proposed as diagnostic tools. Here, we evaluated miRNAs signature in meningioma to identify novel biomarkers of tumour progression.

AB - Meningioma is the most common primary tumour affecting the central nervous system; it is classified as benign (WHO I, ~80%), atypical (WHO II, ~15-20%) and anaplastic/malignant (WHO III, ~1-3%). The 3-year recurrence rate in WHO I meningioma is estimated in about 50% and it is much greater in WHO II and III tumours. MicroRNAs (miRNAs) represent a large class of small RNAs driving regulation of gene expression at post-transcriptional level and playing a role in cell proliferation, differentiation, apoptosis and carcinogenesis. Several studies showed that miRNAs are involved in tumour progression and therefore proposed as diagnostic tools. Here, we evaluated miRNAs signature in meningioma to identify novel biomarkers of tumour progression.

UR - https://pearl.plymouth.ac.uk/pms-research/147

M3 - Abstract

T2 - 25th Biennial Congress of the European Association for Cancer Research (EACR25)

Y2 - 30 June 2018 through 3 July 2018

ER -

High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma

Abstract

Conference

Access to Document

Other files and links

Fingerprint

Cite this